Search results for "Highlights"
Highlights
A single-center, case-control study of patients who were hospitalized with COVID-19 found a link between elevated levels of IL-6, IL-8, and interferon-γ-induced protein 10 and mortality risk, regardless of whether patients had type 2 diabetes.
January 2022
Highlights
Patients with diabetes who were taking any beta-blocker, a beta-1 selective beta-blocker, or a specific beta-blocker had significantly higher risk for all-cause mortality versus patients with diabetes who were not taking a beta-blocker.
April 2018
Highlights
Between 2007 and 2014, more Medicare beneficiaries were newly prescribed metformin, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors, while fewer received long-acting sulfonylureas or thiazolidinediones.
March 2018
Highlights
Patients with type 2 diabetes who had Roux-en-Y gastric bypass surgery maintained significant, although shrinking, improvements in HbA1c compared to those receiving lifestyle and medical management.
February 2018
Highlights
Participants were randomized to receive either ezetimibe or placebo in addition to background simvastatin, and the subgroup of patients with diabetes was compared to those without the disease.
January 2018
Highlights
The updated guideline from the American Academy of Neurology supports offering tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, gabapentinoids, and/or sodium channel blockers to reduce pain from diabetic neuropathy.
January 2022
Keeping tabs
The differences among ethnic groups may be due to genetic, environmental, and behavioral factors, and highlight the need to identify ways to reduce disparities, they said.
April 2017
Highlights
Tirzepatide, a not-yet-approved dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, was tested against placebo and semaglutide in recent studies.
July 2021
Highlights
The population-based retrospective cohort study included 22,124 type 2 diabetes patients from a British national primary care database, 4,444 of whom had taken dapagliflozin.
March 2017
Highlights
While the meta-analysis also found durable reductions in macrovascular complications and mortality with sodium-glucose cotransporter-2 (SGLT-2) inhibitors versus placebo, there were insufficient data comparing the drug class to other
December 2021